[go: up one dir, main page]

MX393395B - Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. - Google Patents

Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.

Info

Publication number
MX393395B
MX393395B MX2019010354A MX2019010354A MX393395B MX 393395 B MX393395 B MX 393395B MX 2019010354 A MX2019010354 A MX 2019010354A MX 2019010354 A MX2019010354 A MX 2019010354A MX 393395 B MX393395 B MX 393395B
Authority
MX
Mexico
Prior art keywords
preparation
amine derivative
sub
heteroaryl
medical uses
Prior art date
Application number
MX2019010354A
Other languages
English (en)
Other versions
MX2019010354A (es
Inventor
Biao Lu
Feng He
Shenglan Wang
Weikang Tao
Xiaodong Shen
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019010354A publication Critical patent/MX2019010354A/es
Publication of MX393395B publication Critical patent/MX393395B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un derivado de heteroaril[4,3-c]pirimidin-5-amina, un método de preparación del mismo y usos médicos del mismo. Específicamente, un derivado de heteroaril[4,3-c]pirimidin-5-amina representado por una fórmula general (I), un método de preparación del mismo, una composición farmacéutica que contiene el derivado y usos del mismo como agentes terapéuticos, en particular, un uso como un antagonista del receptor A2a y un uso en la preparación de un medicamento para el tratamiento de afecciones o síntomas que se mejoran al inhibir el receptor A2a ; varios grupos sustituyentes en la fórmula general (I) tienen los significados idénticos a los de la especificación. (ver fórmula)
MX2019010354A 2017-03-16 2018-03-15 Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. MX393395B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710156742 2017-03-16
CN201710982734 2017-10-20
PCT/CN2018/079086 WO2018166493A1 (zh) 2017-03-16 2018-03-15 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2019010354A MX2019010354A (es) 2019-10-22
MX393395B true MX393395B (es) 2025-03-24

Family

ID=63523780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010354A MX393395B (es) 2017-03-16 2018-03-15 Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.

Country Status (13)

Country Link
US (1) US11312705B2 (es)
EP (1) EP3575301A4 (es)
JP (1) JP7111733B2 (es)
KR (1) KR20190129851A (es)
CN (1) CN109963854B (es)
AU (1) AU2018233367B2 (es)
BR (1) BR112019017108A2 (es)
CA (1) CA3054976A1 (es)
MX (1) MX393395B (es)
RU (1) RU2764655C2 (es)
TW (1) TWI772386B (es)
UA (1) UA125592C2 (es)
WO (1) WO2018166493A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900680T1 (it) 2014-02-13 2020-01-14 Incyte Corp Ciclopropilammine come inibitori di lsd1
KR102352408B1 (ko) 2014-02-13 2022-01-18 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
MX373154B (es) 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
ES3011209T3 (en) 2015-08-12 2025-04-07 Incyte Holdings Corp Salts of an lsd1 inhibitor
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
AU2019227607C1 (en) * 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
JP7490631B2 (ja) 2018-07-05 2024-05-27 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
TWI820209B (zh) 2018-09-12 2023-11-01 大陸商迪哲（江蘇）醫藥股份有限公司 三唑并－嘧啶化合物及其用途
WO2020052648A1 (zh) * 2018-09-14 2020-03-19 江苏恒瑞医药股份有限公司 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
CN110903291B (zh) * 2018-09-14 2021-09-03 江苏恒瑞医药股份有限公司 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
KR102653800B1 (ko) 2018-11-30 2024-04-01 머크 샤프 앤드 돔 엘엘씨 아데노신 수용체 길항제로서의 9-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도
WO2020132197A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
WO2020128036A1 (en) * 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
JP7625524B2 (ja) 2019-01-11 2025-02-03 オメロス コーポレーション がんを処置するための方法および組成物
TWI829857B (zh) * 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN111848625B (zh) * 2019-04-24 2022-07-26 江苏恒瑞医药股份有限公司 一种杂芳基并[4,3-c]嘧啶-5-胺类化合物的制备方法及中间体
WO2021156439A1 (en) 2020-02-06 2021-08-12 Astrazeneca Ab Triazole compounds as adenosine receptor antagonists
EP4126873A1 (en) * 2020-03-26 2023-02-08 Heptares Therapeutics Limited 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer
EP4126871B1 (en) * 2020-03-26 2024-05-08 Heptares Therapeutics Limited Triazolone compounds
CN115867282B (zh) * 2020-03-26 2025-05-27 奈克斯拉制药英国有限公司 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
WO2021191376A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69820866T2 (de) * 1997-03-24 2004-12-30 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
US6545000B1 (en) 1998-09-22 2003-04-08 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
WO2003068776A1 (en) * 2002-02-15 2003-08-21 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
PT1863818E (pt) * 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
DE102006008880A1 (de) 2006-02-27 2007-09-06 Merck Patent Gmbh Aminopyrimidinderivate
WO2007116106A1 (es) 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
AU2009222047A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
US8796297B2 (en) 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
JO3090B1 (ar) 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
RU2012153675A (ru) 2010-05-12 2014-06-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, пригодные в качестве ингибиторов atr киназы
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
WO2011159302A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Arylindenopyrimidines for treating neurodegenerative and movement disorders while minimizing cardiac toxicity
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
MX2013004733A (es) 2010-10-29 2013-07-02 Pfizer Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
EA023766B1 (ru) * 2011-04-21 2016-07-29 Байер Интеллектчуал Проперти Гмбх Триазолопиридины
TW201326170A (zh) * 2011-12-12 2013-07-01 拜耳製藥公司 經取代之三唑并吡啶
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
PE20170303A1 (es) 2014-06-17 2017-04-19 Chiesi Farm Spa Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
TN2017000204A1 (en) * 2014-12-23 2018-10-19 Novartis Ag Triazolopyrimidine compounds and uses thereof
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
AU2019227607C1 (en) * 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

Also Published As

Publication number Publication date
CN109963854B (zh) 2022-04-12
RU2019131111A (ru) 2021-04-16
AU2018233367A1 (en) 2019-08-29
RU2019131111A3 (es) 2021-04-16
TW201835083A (zh) 2018-10-01
RU2764655C2 (ru) 2022-01-19
UA125592C2 (uk) 2022-04-27
MX2019010354A (es) 2019-10-22
JP7111733B2 (ja) 2022-08-02
EP3575301A4 (en) 2020-08-05
CA3054976A1 (en) 2018-09-20
KR20190129851A (ko) 2019-11-20
JP2020510012A (ja) 2020-04-02
AU2018233367B2 (en) 2021-08-12
US20210032224A1 (en) 2021-02-04
CN109963854A (zh) 2019-07-02
TWI772386B (zh) 2022-08-01
WO2018166493A1 (zh) 2018-09-20
US11312705B2 (en) 2022-04-26
EP3575301A1 (en) 2019-12-04
BR112019017108A2 (pt) 2020-04-07

Similar Documents

Publication Publication Date Title
MX393395B (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX374346B (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
NZ708593A (en) Novel pyrazole derivative
PH12014502040A1 (en) Heterocyclyl compounds
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201992679A1 (ru) N-замещенные индольные производные
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
MX382128B (es) Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.
JOP20190183B1 (ar) معدِلات مستقبلات الاستروجين
GB201302704D0 (en) Therapeutic compounds
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
EA201792170A1 (ru) Производные индола
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.